Bellicum Pharmaceuticals Inc logo

BLCM

Bellicum Pharmaceuticals Inc

$1.43

Earnings Summary

Revenue
$0Mn
Net Profits
$-7.56Mn
Net Profit Margins
-Inf%
PE Ratio
51

Highlights

Revenue:

Bellicum Pharmaceuticals Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, Bellicum Pharmaceuticals Inc has generated 100% jump in its revenue since last 3-months.

Net Profits:

Bellicum Pharmaceuticals Inc’s net profit jumped 32.88% since last year same period to $-7.56Mn in the Q1 2022. On a quarterly growth basis, Bellicum Pharmaceuticals Inc has generated -161.85% fall in its net profits since last 3-months.

Net Profit Margins:

Bellicum Pharmaceuticals Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, Bellicum Pharmaceuticals Inc has generated -Inf% fall in its net profit margins since last 3-months.

PE Ratio:

Bellicum Pharmaceuticals Inc’s price-to-earnings ratio after this Q1 2022 earnings stands at 51.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Bellicum Pharmaceuticals Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.69
EPS Estimate Current Year
-0.69

Highlights

EPS Estimate Current Quarter:

Bellicum Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.69 - a -2.99% fall from last quarter’s estimates.

EPS Estimate Current Year:

Bellicum Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.69.

Key Ratios

Key ratios of the Bellicum Pharmaceuticals Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.25
Return on Assets (ROA)
-0.43
Return on Equity (ROE)
-0.43
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Bellicum Pharmaceuticals Inc’s earning per share (EPS) jumped 76.85% since last year same period to -0.25 in the Q1 2022. This indicates that the Bellicum Pharmaceuticals Inc has generated 76.85% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Bellicum Pharmaceuticals Inc’s return on assets (ROA) stands at -0.43.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Bellicum Pharmaceuticals Inc’s return on equity (ROE) stands at -0.43.

Dividend Per Share (DPS):

Bellicum Pharmaceuticals Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-12
-0.67
-0.25
62.69%

Company Information

Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company's next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T cell therapies. Bellicum's GoCAR-T® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms.

Organisation
Bellicum Pharmaceuticals Inc
Headquarters
3730 Kirby Drive, Houston, TX, United States, 77098
Employees
16
Industry
Health Technology
CEO
Richard Fair